BiotechTube

IONIS-DMPKRx + Placebo

Phase 1/2Completed
0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Myotonic Dystrophy Type 1

Conditions

Myotonic Dystrophy Type 1

Trial Timeline

Dec 1, 2014 → Aug 1, 2016

NCT ID
NCT02312011

About IONIS-DMPKRx + Placebo

IONIS-DMPKRx + Placebo is a phase 1/2 stage product being developed by Ionis Pharmaceuticals for Myotonic Dystrophy Type 1. The current trial status is completed. This product is registered under clinical trial identifier NCT02312011. Target conditions include Myotonic Dystrophy Type 1.

What happened to similar drugs?

0 of 2 similar drugs in Myotonic Dystrophy Type 1 were approved

Approved (0) Terminated (0) Active (2)
🔄Del-desiran (AOC 1001)Avidity BiosciencesPhase 3
🔄DYNE-101 + PlaceboDyne TherapeuticsPhase 3

Hype Score Breakdown

Clinical
9
Activity
8
Company
12
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT02312011Phase 1/2Completed

Competing Products

16 competing products in Myotonic Dystrophy Type 1

See all competitors
ProductCompanyStageHype Score
TideglusibAMO PharmaPre-clinical
20
TideglusibAMO PharmaPhase 2
25
Tideglusib + PlaceboAMO PharmaPhase 2/3
28
TideglusibAMO PharmaPhase 2/3
35
VX-670Vertex PharmaceuticalsPhase 2
42
VX-670 + PlaceboVertex PharmaceuticalsPhase 1/2
39
SAR446268SanofiPhase 1/2
39
rhIGF-I/rhIGFBP-3 + placeboInsmedPhase 2
32
Del-desiran (AOC 1001)Avidity BiosciencesPhase 3
44
ARO-DM1 Intravenous (IV) Infusion + Placebo Intravenous (IV) Infusion + ARO-DM1 subcutaneous (SC) injection + Placebo Subcutaneous (SC) InjectionArrowhead PharmaceuticalsPhase 1/2
36
DYNE-101 + PlaceboDyne TherapeuticsPhase 3
41
DYNE-101 + PlaceboDyne TherapeuticsPhase 1/2
33
Pitolisant Oral Tablet + Placebo oral tabletHarmony BiosciencesPhase 2
29
PGN-EDODM1PepGenPhase 2
32
PGN-EDODM1PepGenPhase 2
32
PGN-EDODM1 for infusionPepGenPhase 1
19